Search research articles
Contact Us
Filters
Showing results (361-370 of 395) with videos related to
Page
of 40
Sort By:
Scientific Reports
|
November 14, 2025
Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients
Fatemeh Ahmadiharchegani, Rebecca A Tobin, Chiara Degan, et al.
Human Mutation
|
July 26, 2019
GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
Arnold J J Reuser, Ans T van der Ploeg, Yin-Hsiu Chien, et al.
Journal of Neuromuscular Diseases
|
February 20, 2025
A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing Landscape
Leanne M Ward, David R Weber, Sze Choong Wong, et al.
British Journal of Cancer
|
November 22, 2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S Boeck, A Jung, R P Laubender, et al.
Journal of Neuromuscular Diseases
|
November 19, 2023
Findings from the Longitudinal CINRG Becker Natural History Study
Paula R Clemens, Heather Gordish-Dressman, Gabriela Niizawa, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104
Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
BMC Cancer
|
August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Journal of Neurology
|
February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology
|
December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Gut
|
July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Page
of 40
Search research articles
Search
Showing results (361-370 of 395) with videos related to
Sort By:
Page
of 40
Scientific Reports
|
November 14, 2025
Circulating protein biomarkers identified in two independent clinical trial cohorts of glucocorticoid-naive Duchenne muscular dystrophy patients
Fatemeh Ahmadiharchegani, Rebecca A Tobin, Chiara Degan, et al.
Human Mutation
|
July 26, 2019
GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
Arnold J J Reuser, Ans T van der Ploeg, Yin-Hsiu Chien, et al.
Journal of Neuromuscular Diseases
|
February 20, 2025
A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing Landscape
Leanne M Ward, David R Weber, Sze Choong Wong, et al.
British Journal of Cancer
|
November 22, 2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S Boeck, A Jung, R P Laubender, et al.
Journal of Neuromuscular Diseases
|
November 19, 2023
Findings from the Longitudinal CINRG Becker Natural History Study
Paula R Clemens, Heather Gordish-Dressman, Gabriela Niizawa, et al.
Acta Oncologica (Stockholm, Sweden)
|
May 1, 2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104
Stephan Kruger, Stefan Boeck, Volker Heinemann, et al.
BMC Cancer
|
August 29, 2014
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
Steffen Ormanns, Jens T Siveke, Volker Heinemann, et al.
Journal of Neurology
|
February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology
|
December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Gut
|
July 10, 2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, et al.
Page
of 40